ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Toronto, ON, CAN:

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer....

Active, not recruiting
Breast Cancer
Drug: CFI-400945
Drug: Durvalumab

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 4 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Toronto, Ontario, Canada and 199 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 228 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Toronto, Canada and 508 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 121 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Toronto, Canada and 508 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 192 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 360 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 285 other locations

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 140 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems